SNY PE Ratio & Valuation,Is SNY Overvalued

SNY Relative Valuation

SNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNY is overvalued; if below, it's undervalued.

Historical Valuation

Sanofi SA (SNY) is now in the Fair zone, suggesting that its current forward PE ratio of 10.08 is considered Fairly compared with the five-year average of 10.38. The fair price of Sanofi SA (SNY) is between 40.76 to 67.43 according to relative valuation methord.

Relative Value

Fair Zone

40.76-67.43

Current Price：48.68

Fair

10.08

8.08

EV/EBITDA

Sanofi SA. (SNY) has a current EV/EBITDA of 8.08. The 5-year average EV/EBITDA is 9.08. The thresholds are as follows: Strongly Undervalued below 7.67, Undervalued between 7.67 and 8.38, Fairly Valued between 9.79 and 8.38, Overvalued between 9.79 and 10.50, and Strongly Overvalued above 10.50. The current Forward EV/EBITDA of 8.08 falls within the Undervalued range.

8.95

EV/EBIT

Sanofi SA. (SNY) has a current EV/EBIT of 8.95. The 5-year average EV/EBIT is 10.08. The thresholds are as follows: Strongly Undervalued below 8.56, Undervalued between 8.56 and 9.32, Fairly Valued between 10.85 and 9.32, Overvalued between 10.85 and 11.61, and Strongly Overvalued above 11.61. The current Forward EV/EBIT of 8.95 falls within the Undervalued range.

2.22

Sanofi SA. (SNY) has a current PS of 2.22. The 5-year average PS is 2.58. The thresholds are as follows: Strongly Undervalued below 2.12, Undervalued between 2.12 and 2.35, Fairly Valued between 2.80 and 2.35, Overvalued between 2.80 and 3.03, and Strongly Overvalued above 3.03. The current Forward PS of 2.22 falls within the Undervalued range.

9.62

P/OCF

Sanofi SA. (SNY) has a current P/OCF of 9.62. The 5-year average P/OCF is 10.85. The thresholds are as follows: Strongly Undervalued below 8.95, Undervalued between 8.95 and 9.90, Fairly Valued between 11.80 and 9.90, Overvalued between 11.80 and 12.75, and Strongly Overvalued above 12.75. The current Forward P/OCF of 9.62 falls within the Undervalued range.

12.18

P/FCF

Sanofi SA. (SNY) has a current P/FCF of 12.18. The 5-year average P/FCF is 13.73. The thresholds are as follows: Strongly Undervalued below 11.01, Undervalued between 11.01 and 12.37, Fairly Valued between 15.09 and 12.37, Overvalued between 15.09 and 16.45, and Strongly Overvalued above 16.45. The current Forward P/FCF of 12.18 falls within the Undervalued range.

Sanofi SA (SNY) has a current Price-to-Book (P/B) ratio of 1.39. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately 31.54% higher. Relative to its 5-year average P/B ratio of 0.96, the current P/B ratio is about 43.86% higher. Sanofi SA (SNY) has a Forward Free Cash Flow (FCF) yield of approximately 9.25%. Compared to its 3-year average FCF yield of 4.07%, the current FCF yield is approximately 127.58% lower. Relative to its 5-year average FCF yield of 3.82% , the current FCF yield is about 142.56% lower.

1.39

P/B

Median3y

1.05

Median5y

0.96

9.25

FCF Yield

Median3y

4.07

Median5y

3.82

Competitors Valuation Multiple

The average P/S ratio for SNY's competitors is 4.25, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.22, which is -47.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SNY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SNY in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Sanofi SA (SNY) currently overvalued or undervalued?

What is Sanofi SA (SNY) fair value?

SNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sanofi SA (SNY) is between 40.76 to 67.43 according to relative valuation methord.

How does SNY's valuation metrics compare to the industry average?

What is the current P/B ratio for Sanofi SA (SNY) as of Dec 15 2025?

As of Dec 15 2025, Sanofi SA (SNY) has a P/B ratio of 1.39. This indicates that the market values SNY at 1.39 times its book value.

What is the current FCF Yield for Sanofi SA (SNY) as of Dec 15 2025?

As of Dec 15 2025, Sanofi SA (SNY) has a FCF Yield of 9.25%. This means that for every dollar of Sanofi SA’s market capitalization, the company generates 9.25 cents in free cash flow.

What is the current Forward P/E ratio for Sanofi SA (SNY) as of Dec 15 2025?

As of Dec 15 2025, Sanofi SA (SNY) has a Forward P/E ratio of 10.08. This means the market is willing to pay $10.08 for every dollar of Sanofi SA’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sanofi SA (SNY) as of Dec 15 2025?

As of Dec 15 2025, Sanofi SA (SNY) has a Forward P/S ratio of 2.22. This means the market is valuing SNY at $2.22 for every dollar of expected revenue over the next 12 months.

SNY Valuation